Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Vertex Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Vertex Pharma Acquires CTP-656 from Concert Pharma 13
Vertex Pharma Acquires Cystic Fibrosis Assets from AmorChem 15
Partnerships 16
X-Chem Enters into Agreement with Vertex Pharma 16
Vertex Pharma Enters into Research Collaboration with CRISPR Therapeutics 17
Vertex Pharma Enters into Co-Development Agreement with Parion Sciences 18
Vertex Pharma Extends Co-Development Agreement With Cystic Fibrosis Foundation 19
Licensing Agreements 21
Merck Enters into Licensing Agreement with Vertex Pharma 21
Vertex Pharma Enters into Licensing Agreement with Moderna Therapeutics 22
Enterome Bioscience Enters into Licensing Agreement with Vertex Pharma 23
Vertex Pharma Enters into Licensing Agreement with Janssen Pharma for VX-787 24
EIP Pharma Enters into Licensing Agreement with Vertex Pharma 25
Vertex Pharma Enters into Licensing Agreement with BioAxone Biosciences for VX-210 26
Asset Transactions 27
Trek Therapeutics Acquires Rights to Two Antiviral Inhibitors from Vertex Pharma 27
Spero Therapeutics Acquires Rights to Novel Gyrase Inhibitors from Vertex Pharma 28
Janssen Pharma Acquires Royalty Rights To Incivo From Vertex Pharma For US$152 Million 29
Vertex Pharmaceuticals Inc – Key Competitors 30
Vertex Pharmaceuticals Inc – Key Employees 31
Vertex Pharmaceuticals Inc – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 35
Financial Announcements 35
Oct 25, 2017: Vertex Reports Third-Quarter 2017 Financial Results 35
Jul 26, 2017: Vertex Reports Second-Quarter 2017 Financial Results 38
Apr 27, 2017: Vertex Reports First-Quarter 2017 Financial Results 41
Jan 25, 2017: Vertex Reports Full-Year and Fourth-Quarter 2016 Financial Results 44
Oct 25, 2016: Vertex Reports Third Quarter 2016 Financial Results 46
Jul 27, 2016: Vertex Reports Second Quarter 2016 Financial Results 48
Apr 27, 2016: Vertex Reports First Quarter 2016 Financial Results 50
Jan 27, 2016: Vertex Reports Full-Year and Fourth Quarter 2015 Financial Results 54
Corporate Communications 57
Oct 17, 2017: Vertex Announces 10-Year, $500 Million Corporate Giving Commitment 57
Sep 06, 2017: Vertex Appoints Tom Graney as Senior Vice President and Chief Financial Officer 58
Jun 08, 2017: Vertex Names Dr. Alan Garber, Provost of Harvard University, to its Board of Directors 59
Dec 02, 2016: Vertex Pharmaceuticals Announces Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 60
Government and Public Interest 61
Nov 01, 2017: Vertex Announces New $750,000 Program to Support the Work of the Next Generation of Cystic Fibrosis Researchers 61
May 04, 2017: Vertex Grants $1 Million to 15 Non-profit Organizations to Advance Initiatives for People Living with Cystic Fibrosis 62
Feb 24, 2016: Vertex Awards $1 Million in Grants to 18 Non-profit Organizations to Advance Initiatives for People Living with Cystic Fibrosis 63
Product Approvals 64
Jan 20, 2017: Concert Pharmaceuticals Receives FDA Orphan Drug Designation for CTP-656 for the Treatment of Cystic Fibrosis 64
Clinical Trials 65
Nov 03, 2017: Vertex Announces Presentation of Data from Triple Combination (VX-440, VX-152 and VX-659) Regimen Studies at North American Cystic Fibrosis Conference 65
Jan 17, 2017: Concert Pharmaceuticals Provides Further Details on CTP-656 Development in U.S. and Europe 66
Dec 21, 2016: Concert Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating CTP-656 for the Treatment of Cystic Fibrosis 67
Oct 27, 2016: Concert Pharmaceuticals Presents Poster at 2016 North American Cystic Fibrosis Conference 68
Oct 25, 2016: Vertex Announces Planned Initiation of Phase 2 Study Evaluating the Next-Generation Corrector VX-152 in Triple Combination Regimens to Treat the Underlying Cause of Cystic Fibrosis 69
Oct 25, 2016: Vertex Announces Planned Initiation of Phase 2 Study Evaluating the Next-Generation Corrector VX-440 in Triple Combination Regimens to Treat the Underlying Cause of Cystic Fibrosis 70
Oct 25, 2016: Vertex to Begin Clinical Development of Third Next-Generation Corrector VX-659 71
Jun 10, 2016: Concert Pharmaceuticals Presents CTP-656 Phase 1 Results at European Cystic Fibrosis Conference 72
Apr 28, 2016: Concert Pharmaceuticals Announces Positive Data from Multiple Dose Phase 1 Clinical Trial of CTP-656, Lead Candidate for the Treatment of Cystic Fibrosis 73
Feb 29, 2016: Concert Pharmaceuticals Announces CTP-656 Solid Dose Phase 1 Results Confirmed Superior Pharmacokinetic Profile to Kalydeco 74
Other Significant Developments 75
Jan 08, 2017: Vertex Provides Update on Business and Financial Performance and Research and Development Programs 75
Jan 10, 2016: Vertex Outlines 2016 Business Priorities to Support the Discovery and Development of New Transformative Medicines for the Treatment of Cystic Fibrosis and Other Serious Diseases 78
Appendix 82
Methodology 82
About GlobalData 82
Contact Us 82
Disclaimer 82
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Vertex Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Vertex Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
Vertex Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Vertex Pharma Acquires CTP-656 from Concert Pharma 13
Vertex Pharma Acquires Cystic Fibrosis Assets from AmorChem 15
X-Chem Enters into Agreement with Vertex Pharma 16
Vertex Pharma Enters into Research Collaboration with CRISPR Therapeutics 17
Vertex Pharma Enters into Co-Development Agreement with Parion Sciences 18
Vertex Pharma Extends Co-Development Agreement With Cystic Fibrosis Foundation 19
Merck Enters into Licensing Agreement with Vertex Pharma 21
Vertex Pharma Enters into Licensing Agreement with Moderna Therapeutics 22
Enterome Bioscience Enters into Licensing Agreement with Vertex Pharma 23
Vertex Pharma Enters into Licensing Agreement with Janssen Pharma for VX-787 24
EIP Pharma Enters into Licensing Agreement with Vertex Pharma 25
Vertex Pharma Enters into Licensing Agreement with BioAxone Biosciences for VX-210 26
Trek Therapeutics Acquires Rights to Two Antiviral Inhibitors from Vertex Pharma 27
Spero Therapeutics Acquires Rights to Novel Gyrase Inhibitors from Vertex Pharma 28
Janssen Pharma Acquires Royalty Rights To Incivo From Vertex Pharma For US$152 Million 29
Vertex Pharmaceuticals Inc, Key Competitors 30
Vertex Pharmaceuticals Inc, Key Employees 31
Vertex Pharmaceuticals Inc, Subsidiaries 33